Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Ephedrine Sulfate Injection USP, 50 mg/mL single-dose vials, the company announced through an exchange filing.
Ephedrine Sulfate Injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. The drug will be manufactured at the group’s injectable manufacturing facility at Jarod, near Vadodara (India).
Ephedrine Sulfate Injection USP, 50 mg/mL had annual sales of USD 52 mn in the United States.
The group now has 368 approvals and has so far filed over 440* ANDAs since the commencement of the filing process in FY 2003-04.
'We Want To Live...': Iceland Cricket's Witty Remark On Saim Ayub's 3 Consecutive Ducks Goes Viral Ahead Of IND Vs PAK Asia Cup Super 4 Match
Mumbai News: Special NIA Court Orders Release Of 59-Year-Old Businessman’s Flat Attached Over Tenant’s Alleged ISIS Links
Mumbai: Survey Reveals Over Half Of Senior Citizens Avoid Online Banking Due To Fear, Digital Illiteracy
Mumbai Cyber Fraud: 26-Year-Old Corporate Lawyer Duped Of ₹9.73 Lakh Through Fake Stock Trading Apps, FIR Registered At Dadar Police Station
